[1] 李家泰.临床药理学[M]. 第二版.北京:人民卫生出版社,1998:242,489-490.
[2] 王仁云.抗真菌药与心血管药物的相互作用[J]. 药学实践杂志,2002,20(1):52-55.
[3] 王爱平,王亮春,李若瑜.三种抗真菌药物治疗甲真菌病的安全性评价[J]. 中华皮肤科杂志,2004,37(8):498-499.
[4] Garcia Rodriguez LA,Duque A,Castellsague J,et al.A cohort study on the risk of acute liver injury among users of ketecon-azole and other antifungal dross[J]. Br J Clin Pharmacol,1999,48(6):847-852.
[5] Chang CH,Young-Xu Y,Kurth T,et al.The safety of oral antifun-gal treatments for superficial dermatophytosis and onychomyco-sis:a mete-analysis[J]. Am J Med,2007,120 (9):791-798.
[6] 刘龙,景宝洁,吴璐.特比萘芬引致的肝损害及防治[J]. 药物不良反应杂志,2008,10(4):271-273.
[7] Vickers AE,Sinclair JR,Zollinger M,et al.Mutiple cytochrome P-450s involved in the metabolism of terbinafine snggest a limit-ed potential for drug-drug interactions[J]. Drug Metab Dispos,1999,27(9):1029-1038.
[8] Hall M,Monka C,Krupp P,et al.Safety of oral terbinafine:re-sults of s postmarketing surveillance study in 25,884 patients[J]. Arch Dennatol,1997,133(10):1213-1219.
[9] 陈平.抗真菌药物不良反应[J]. 医师进修杂志,2005,28(11):12-14.
[10] Gupta AK,Chwetzoff E,Del Rosso J,et al.Hepatic safety of itraconazole[J]. J Cuten Med Surg,2002,6(3):210-213.
[11] 周琼.抗真菌药物与其他药物的相互作用及机制[J]. 医药导报,2002,21(增刊):76-77.
[12] 徐海涛,翻秀勤,韩瑞顺,等.与伊曲康唑、氟康唑、特比萘芬相互作用的药物及其处理[J]. 中国麻风皮肤病杂志,2001,17(4):283-285.
[13] 吴绍熙,郭宁如.抗真菌药物与其他药物间的相互作用及机制[J]. 中国新药杂志,1998,7(5):350-354.
[14] 李新平,马红钗,咎日增.咪唑类抗真菌药物与其他药物的相互作用[J]. 中国临床药学杂志,2003,12(5):320-324.
[15] 张善堂,钱启辉,江国庆.伊曲康唑的药物相互作用[J]. 中国医院药学杂志,1999,19(12):739-741.
[16] 罗权,林玲,张锡宝.伊曲康唑在儿童真菌病中的应用[J]. 国际皮肤性病学杂志,2006,32(5):273-275.
[17] Katz HI.Drug interactions of the newer oral antifungal agents[J]. Br J Dermatol,1999,141 (Suppl 56):26-32.
[18] GuptaAK,Kats HI,Shear NH.Druginteractions with itracon-azole,fluconazole,and terbinafine and their management[J]. J Am Acad Dermatol,1999,41 (2 Pt 1):237-249. |
